Study · Not a test of the peptide alone · 2007

6 results

Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis.

Amori RE, Lau J, Pittas AG

JAMA1 Jul 2007Cited by 755 (Europe PMC)

PMID17622601DOI10.1001/jama.298.2.194PepBankPUB-17622601

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

01HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes, GLP-1 analogues lowered HbA1c versus placebo.
In plain wordsIn adults with type 2 diabetes, GLP-1 drugs as a group lowered HbA1c more than placebo.
Peptide
Liraglutide
Outcome
DecreaseHbA1c change versus placebo
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Measurements
HbA1c weighted mean difference
−0.97%
GLP-1 analogues vs placebo
Source sentences
Summary
Incretins lowered hemoglobin A(1c) compared with placebo (weighted mean difference, -0.97% [95% confidence interval {CI}, -1.13% to -0.81%] for GLP-1 analogues
1 context sentence(design, population, supporting numbers)
Summary · context
Randomized controlled trials were selected if they were at least 12 weeks in duration, compared incretin therapy with placebo or other diabetes medication, and reported hemoglobin A(1c) data in nonpregnant adults with type 2 diabetes.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-1762260101
02HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes, GLP-1 analogues led to weight loss of 1.4 kg versus placebo.
In plain wordsIn adults with type 2 diabetes, GLP-1 drugs as a group led to 1.4 kg more weight loss than placebo.
Peptide
Liraglutide
Outcome
DecreaseWeight change versus placebo
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Measurements
Weight loss
1.4 kg
GLP-1 analogues vs placebo
Source sentences
Summary
Glucagonlike peptide 1 analogues resulted in weight loss (1.4 kg and 4.8 kg vs placebo and insulin, respectively)
1 context sentence(design, population, supporting numbers)
Summary · context
Randomized controlled trials were selected if they were at least 12 weeks in duration, compared incretin therapy with placebo or other diabetes medication, and reported hemoglobin A(1c) data in nonpregnant adults with type 2 diabetes.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-1762260102
03HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes, GLP-1 analogues led to weight loss of 4.8 kg versus insulin.
In plain wordsIn adults with type 2 diabetes, GLP-1 drugs as a group led to 4.8 kg more weight loss than insulin.
Peptide
Liraglutide
Outcome
DecreaseWeight change versus insulin
Study
n: not reported in source
Comparator
Insulin
Outcome group
Body weight · Metabolic and weight
Measurements
Weight loss
4.8 kg
GLP-1 analogues vs insulin
Source sentences
Summary
Glucagonlike peptide 1 analogues resulted in weight loss (1.4 kg and 4.8 kg vs placebo and insulin, respectively)
1 context sentence(design, population, supporting numbers)
Summary · context
Randomized controlled trials were selected if they were at least 12 weeks in duration, compared incretin therapy with placebo or other diabetes medication, and reported hemoglobin A(1c) data in nonpregnant adults with type 2 diabetes.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-1762260103
04HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
In adults with type 2 diabetes, GLP-1 analogues were associated with more nausea.
In plain wordsIn adults with type 2 diabetes, GLP-1 drugs as a group were linked to more nausea.
Peptide
Liraglutide
Outcome
IncreaseNausea
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Measurements
Risk ratio
2.9
nausea, GLP-1 analogues
Source sentences
Summary
Glucagonlike peptide 1 analogues had more gastrointestinal side effects (risk ratio, 2.9 [95% CI, 2.0-4.2] for nausea and 3.2 [95% CI, 2.5-4.4] for vomiting).
1 context sentence(design, population, supporting numbers)
Summary · context
Randomized controlled trials were selected if they were at least 12 weeks in duration, compared incretin therapy with placebo or other diabetes medication, and reported hemoglobin A(1c) data in nonpregnant adults with type 2 diabetes.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-1762260104
05HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
In adults with type 2 diabetes, GLP-1 analogues were associated with more vomiting.
In plain wordsIn adults with type 2 diabetes, GLP-1 drugs as a group were linked to more vomiting.
Peptide
Liraglutide
Outcome
IncreaseVomiting
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Measurements
Risk ratio
3.2
vomiting, GLP-1 analogues
Source sentences
Summary
Glucagonlike peptide 1 analogues had more gastrointestinal side effects (risk ratio, 2.9 [95% CI, 2.0-4.2] for nausea and 3.2 [95% CI, 2.5-4.4] for vomiting).
1 context sentence(design, population, supporting numbers)
Summary · context
Randomized controlled trials were selected if they were at least 12 weeks in duration, compared incretin therapy with placebo or other diabetes medication, and reported hemoglobin A(1c) data in nonpregnant adults with type 2 diabetes.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-1762260105
06HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes, incretins (GLP-1 analogues and DPP4 inhibitors) were noninferior to other hypoglycemic agents for lowering HbA1c.
In plain wordsIn adults with type 2 diabetes, incretin drugs as a group, which include GLP-1 drugs, lowered HbA1c about as well as other diabetes drugs.
Peptide
Liraglutide
Outcome
No significant changeHbA1c versus other hypoglycemic agents
Study
n: not reported in source
Comparator
Other hypoglycemic agents
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
and were noninferior to other hypoglycemic agents.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-1762260106

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 1 completed · 1 stopped early · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

TerminatedNot applicableNCT02244164

Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments.

Erasme University Hospitaln = 5Oct 2014 to 13 Feb 2023

Type 2 Diabetes · Incretinomimetics · Pancreas

Trial page ClinicalTrials.govUpdated 16 Feb 2023

CompletedPhase 3Results postedNCT00856609

The Effects of Exenatide (Byetta ) on Energy Expenditure and Weight Loss in Nondiabetic Obese Subjects

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)n = 1503 Mar 2009 to 19 Sept 2016

Weight Loss · Obesity

Trial page ClinicalTrials.govUpdated 4 Jun 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 18:17 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.